Collaborating to Compete: A Search into Capabilities and Strategic Alliances in the Pharmaceutical Industry
Colaborando para Competir: Búsqueda Dentro de las Capacidades y Alianzas Estratégicas en la Industria Farmacéutica;
Collaborating to Compete: A Search into Capabilities and Strategic Alliances in the Pharmaceutical Industry
| dc.creator | Ohba, Marisa | |
| dc.creator | Figueiredo, Paulo N | |
| dc.date | 2007-06-14 | |
| dc.identifier | https://www.jotmi.org/index.php/GT/article/view/art43 | |
| dc.description | Athough there is a profusion of studies related to strategic alliances and technological capacities which evaluate the issues individually, there is a scarcity of studies with empirical evidence relative to the implications of strategic alliances at the technological capacity configuration. Drawing on a scrutiny of specialised databases (Galé, Dialog, and Business & Industry) covering the 1993-2003 period, this article examines the entry and exit composition of innovative capabilities of 25 pharmaceutical companies’ capabilities involved in such alliances. They are organised in three groups: (i) large pharmaceutical companies (‘big-pharma’); (ii) large bio-pharmaceutical companies (‘bio-pharma’); and (iii) small and research-intensive companies. In terms of strategic alliance implications, a change was observed on the technological capacities’ configuration. The evidence suggests that the criteria for partner choice and technological capacity depend on the objectives and needs of each different group of company. Such type of evidence is important to provide researchers, corporate managers, and policy-makers with a concrete notion of the extent to which such division of innovative labour occurs and the actual changes going on the structure and organisation of innovative activities in the pharmaceutical industry. | en-US |
| dc.description | Titulo: Colaborando para Competir: Búsqueda Dentro de las Capacidades y Alianzas Estratégicas en la Industria Farmacéutica Pese a la existencia de muchos estudios relacionados a las evaluaciones individuales de las alianzas estratégicas y las capacidades tecnológicas, hay escasez de estudios con evidencia empírica relacionados con las implicaciones de las alianzas estratégicas en la configuración de las capacidades tecnológicas. Este artículo organiza un escrutinio de bases de datos (Galé, Dialog, and Business & Industry) entre los años del período 1993-2003, examinando la composición de entrada y salida de las capacidades innovativas de 25 compañías farmacéuticas involucradas en dichas alianzas. Las cuales se organizan en tres grupos (i)¨grandes compañías (grandes farmacéuticas); (ii)grandes compañías bio-farmacéuticas (bio-farma); y (iii) pequeñas compañías y compañías de investigación intensiva. En términos de las implicaciones de las alianzas estratégicas, se observa un cambio en la configuración de las capacidades tecnológicas. La evidencia sugiere que el criterio de para la elección de socios y de las capacidades tecnológicas depende de los objetivos y necesidades de los diversos grupos de compañías. Cada tipo de evidencia es de importancia para proveer a los investigadores, a los gerentes corporativos y los gestores con una noción concreta del grado de de importancia de cada división en las labores innovativas desarrolladas y en los cambio reales que se llevan a cabo en la estructura y la organización de las actividades innovativas en la industria farmacéutica . | es-ES |
| dc.description | Athough there is a profusion of studies related to strategic alliances and technological capacities which evaluate the issues individually, there is a scarcity of studies with empirical evidence relative to the implications of strategic alliances at the technological capacity configuration. Drawing on a scrutiny of specialised databases (Galé, Dialog, and Business & Industry) covering the 1993-2003 period, this article examines the entry and exit composition of innovative capabilities of 25 pharmaceutical companies’ capabilities involved in such alliances. They are organised in three groups: (i) large pharmaceutical companies (‘big-pharma’); (ii) large bio-pharmaceutical companies (‘bio-pharma’); and (iii) small and research-intensive companies. In terms of strategic alliance implications, a change was observed on the technological capacities’ configuration. The evidence suggests that the criteria for partner choice and technological capacity depend on the objectives and needs of each different group of company. Such type of evidence is important to provide researchers, corporate managers, and policy-makers with a concrete notion of the extent to which such division of innovative labour occurs and the actual changes going on the structure and organisation of innovative activities in the pharmaceutical industry. | pt-BR |
| dc.format | application/pdf | |
| dc.language | eng | |
| dc.publisher | Facultad de Economía y Negocios, Universidad Alberto Hurtado | en-US |
| dc.relation | https://www.jotmi.org/index.php/GT/article/view/art43/400 | |
| dc.rights | Copyright (c) 2007 Journal of Technology Management & Innovation | en-US |
| dc.rights | https://creativecommons.org/licenses/by-sa/4.0 | en-US |
| dc.source | Journal of Technology Management & Innovation; Vol. 2 No. 2 (2007); 18-30 | en-US |
| dc.source | Journal of Technology Management & Innovation; Vol. 2 Núm. 2 (2007); 18-30 | es-ES |
| dc.source | 0718-2724 | |
| dc.title | Collaborating to Compete: A Search into Capabilities and Strategic Alliances in the Pharmaceutical Industry | en-US |
| dc.title | Colaborando para Competir: Búsqueda Dentro de las Capacidades y Alianzas Estratégicas en la Industria Farmacéutica | es-ES |
| dc.title | Collaborating to Compete: A Search into Capabilities and Strategic Alliances in the Pharmaceutical Industry | pt-BR |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:eu-repo/semantics/publishedVersion | |
| dc.type | Artículo revisado por pares | en-US |